English, Article edition: Cost Effectiveness of Early Treatment with Oral Aciclovir in Adult Chickenpox Presented in part at the Society of General Internal Medicine 16th Annual Meeting: 1993 Apr; Washington DC. Kenneth J. Smith; Mark S. Roberts

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119197
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost Effectiveness of Early Treatment with Oral Aciclovir in Adult Chickenpox Presented in part at the Society of General Internal Medicine 16th Annual Meeting: 1993 Apr; Washington DC.
Author
  • Kenneth J. Smith
  • Mark S. Roberts
Physical Description
  • article
Notes
  • Treatment of adult chickenpox with aciclovir is controversial because of the relatively high cost of medication and small proven benefits of therapy. A decision-tree model was used to estimate the cost effectiveness of aciclovir, from third-party payer and societal perspectives: the incremental cost per qualityadjusted life-year (QALY) gained was calculated for aciclovir treatment of chickenpox compared with no antiviral therapy in immunocompetent adults who presented within 24 hours of the onset of chickenpox rash. Incremental costs for aciclovir compared with no antiviral treatment were $US42 900 per QALY gained, when viewed from a third-party payer perspective; however, results are sensitive to variation of clinical parameters. From a societal perspective, aciclovir therapy was cost saving compared with no antiviral treatment; aciclovir remained cost saving or cost effective (less than $US50 000 per QALY gained) when probabilities, quality-of-life utility values and costs were varied within clinically plausible ranges, and when other scenarios for chickenpox severity and aciclovir effectiveness were examined. From a societal perspective, oral aciclovir is cost effective, and perhaps cost saving, when given within 24 hours of rash onset in adult chickenpox. The argument for antiviral use may be less strong when viewed from the perspective of a third-party payer.
  • Aciclovir, Varicella-zoster-virus-infections, Cost-effectiveness, Pharmacoeconomics, Quality-adjusted-life-years, Cost-utility, Adults, Antivirals
  • RePEc:wkh:phecon:v:13:y:1998:i:5:p:645-651
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment